BEDMINSTER, N.J. and DUBLIN, May 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2013 financial results and provide an operational update on Thursday, May 9, 2013, at 4:30 p.m. EDT. The conference call will follow the anticipated release of the company's first quarter 2013 financial results earlier that day.
To participate in the call, please dial 877-407-8033 within the United States or 201-689-8033 from outside the United States. A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (inside the United States) or 201-612-7415 (outside the United States). A replay of the call will also be available through the company's website shortly after the call. For both dial-in numbers please use conference ID 411140. The conference call can also be heard live via the investor relations section of the company's website at www.amarincorp.com .
About AmarinAmarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa ® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and is available by prescription. For more information about Vascepa visit www.vascepa.com . For more information about Amarin visit www.amarincorp.com .
CONTACT: Amarin Contact Information: Joseph Bruno Director, Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) 719-1315 email@example.com